Heat Biologics, Inc. (HTBX)

Oncology Corporate Profile

Stock Performance

0.6917
-0.0283

HQ Location

100 Europa Drive, Suite 420
Chapel Hill, NC 27517

Company Description

Heat Biologics, Inc. is a clinical-stage biopharmaceutical company focused on developing its novel, "off-the-shelf" ImPACT therapeutic vaccines to combat a wide range of cancers. Their ImPACT Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells.

Website: http://www.heatbio.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
vesigenurtucel-L / HS-410cytotoxic t-cell specific adjuvantBladder cancerII
vesigenurtucel-L (+cyclophosphamide) / HS-110cytotoxic t-cell specific adjuvantNon Small Cell Lung Cancer (NSCLC)II
vesigenurtucel-L (+nivolumab) / HS-110cytotoxic t-cell specific adjuvantNon Small Cell Lung Cancer (NSCLC)II

View additional information on product candidates here »

Source: http://www.heatbio.com

Recent News Headlines

5/27/2017 06:18 am

5/27/2017 06:18 am

5/27/2017 06:18 am

5/27/2017 06:18 am

5/27/2017 06:18 am

5/11/2017 12:18 pm

5/11/2017 12:18 pm

5/11/2017 12:18 pm

5/11/2017 12:18 pm

5/11/2017 12:18 pm

5/11/2017 12:18 am

5/11/2017 12:18 am

5/11/2017 12:18 am

5/11/2017 12:18 am

5/11/2017 12:18 am

5/2/2017 06:18 am

5/2/2017 06:18 am

5/2/2017 06:18 am

5/2/2017 06:18 am

5/1/2017 06:18 am

4/26/2017 12:18 am

Heat Biologics Reports Fiscal Year 2016 Financial Results

3/31/2017 11:00 am

[GlobeNewswire] - DURHAM, N.C., March 31, 2017-- Heat Biologics, Inc., a leader in the development of immunotherapies designed to activate a patient’ s immune system against cancer, reported financial results for the fiscal ...

Heat Biologics Closes Public Offering of 5,000,000 Shares of Common Stock

3/28/2017 08:00 pm

[GlobeNewswire] - DURHAM, N.C., March 28, 2017-- Heat Biologics, Inc., a leader in the development of immunotherapies designed to activate a patient’ s immune system against cancer, announced the closing of an underwritten ...